nSTRIDE® APS is an Autologous Anti-Inflammatory treatment, which is designed to treat joint pain associated with knee osteoarthritis. In laboratory testing, nSTRIDE®APS has been shown to protect cartilage tissue.
nSTRIDE® APS will be injected directly in the knee joint. Positive outcomes may be possible due to the presence of high concentrations of anti-inflammatory proteins. The “good” proteins extracted by the nSTRIDE® system which in cell cultures have been shown to block cartilage destruction in Osteoarthritis. The joint pain may be reduced, and the joint function may be improved. The treatment is designed to be a single injection therapy in the doctor’s office.
The nSTRIDE® APS Kit processes the patient’s own blood in the doctor’s office to concentrate white blood cells, platelets and plasma proteins into a small volume of plasma. The output is approximately 2-3 cc of anti-inflammatory solution.
2-3 cc of final output will be injected directly in the knee joint.
nSTRIDE® APS may significantly decrease pain, reduce stiffness and help restore mobility and flexibility.
Pain relief may be expected after one to two weeks.
Based on preclinical and early clinical results, patients may expect to see benefits for up to 24-36
months.
Clinical studies have demonstrated the effectiveness of one injection. These studies suggest one injection can last up to 24-36 months.
To find out more about nSTRIDE® aps treatment simply contact our team.
@DeanBoyce6 @ArenaSwansea @BSSHand Fantastic meeting. Thanks for hosting Swansea!